Drug

• NanoViricides will begin a Phase II clinical trial next week for NV-387, an oral gummy drug designed to treat the Bundibugyo Ebola virus. • The trial responds to an expanding outbreak in the Democratic Republic of Congo where the crude fatality rate has reached 48%. • A successful treatment could reduce deaths and slow the spread of the virus during the largest outbreak currently affecting the region.

• A new modelling study published in The Lancet suggests European patients may face longer waits for new medicines due to US efforts to lower drug prices. • Researchers analyzed 195 patented medicines that represent $87.9 billion of annual spending in the United States. • Pharmaceutical companies may delay launching products in lower-price markets if the US forces prices to match those in high-income countries like France or Germany.

• NanoViricides will begin a clinical trial next week for the oral drug NV-387 to treat an expanding Ebola outbreak in the Democratic Republic of Congo. • The current outbreak of the Bundibugyo Ebolavirus variant has a 48% crude fatality rate and no approved treatment or vaccine. • The virus has spread into displacement camps hosting over 4.4 million people, creating a high-risk population with poor sanitation and medical resources.

• Clinical trials for the oral drug NV-387 will begin to treat a rapidly expanding outbreak of the Bundibugyo Ebolavirus in the Democratic Republic of the Congo. • The virus has spread into displacement camps hosting over 4.4 million people who lack adequate drinking water, sanitation, and medical resources. • This trial is critical because there is currently no approved treatment or vaccine for this specific variant of the Ebolavirus Disease.

• The FDA approved Scholar Rock's drug Isembyld for adults and children aged 2 and older who are already using therapies for spinal muscular atrophy (SMA). • A late-stage clinical trial showed that patients using Isembyld alongside an SMN2-targeting drug improved their motor skills after one year, while the placebo group declined. • This approval provides a new treatment option specifically targeting muscle loss for patients with SMA, a genetic condition affecting neurons that control movement.

Man, who cannot be named to protect anonymity of his victim, admits scores of criminal offencesA man has pleaded guilty to drugging and sexually assaulting his wife over a period of 20 years as he admitted 60 criminal offences.The man, who cannot be named in order to protect the anonymity of his victim, is in his 60s and before his arrest lived in Stockport, Greater Manchester. Continue reading...

• The White House signed secretive agreements with 26 drugmakers that may exempt various medicines from mandatory price reductions in Medicare. • A new analysis indicates these deals could drastically reduce the projected savings from the "most-favored nation" pricing policy, which aims to align U.S. drug costs with lower prices paid abroad. • These exemptions could limit the government's ability to lower prescription costs for millions of Medicare beneficiaries.

• The FDA approved a new treatment for pancreatic cancer to help patients fighting one of the deadliest forms of the disease. • Drug manufacturers may offer expanded access programs that allow patients who do not qualify for clinical trials to receive these newly approved therapies. • Patients and families can coordinate with oncologists at National Cancer Institute-designated facilities to identify which access programs are currently active.

• The FDA approved six cancer drugs in August 2026, including a new pill for pancreatic cancer called Rasonque. • Patients taking Rasonque lived a median of 13.2 months compared to 6.7 months for those on chemotherapy, reducing the risk of death by roughly 60%. • This approval provides a significant survival increase for pancreatic cancer patients in a disease where gains are typically measured in weeks.

• A new wave of illegal fruity vapes has emerged, posing health risks to users, particularly among youth and young adults. • Researchers and healthcare providers are noting an increasing trend of children being prescribed GLP-1s, a type of medication typically used to treat type 2 diabetes and obesity. • The emergence of these health issues and the growing need for effective treatments, such as the pancreatic cancer drug RevMed, highlights the importance of continued research and development in the healthcare sector.

• The FDA has expanded its approval of a Bayer lung cancer drug, although the specific details of the expansion are not provided in the given information. • The announcement is part of a broader set of biotech news that includes updates on UniQure and an AI effort to manage heart failure. • The expansion of the Bayer lung cancer drug approval may improve treatment options for patients with lung cancer, potentially leading to better health outcomes.

Rubio visits Ecuador and welcomes cooperation after campaign of unilateral strikes on alleged ‘narco-terrorists’US secretary of state Marco Rubio gave new clarity on the approach toward combating drug trafficking in Latin American waters, saying the Trump administration was focused on working with allied countries and aligning with their laws but insisting the military will “still blow up ships if need be.”The public acknowledgment of a shift in US strategy comes a year after Washington began a campaign of unilateral deadly strikes against those it calls “narco-terrorists” operating boats in international waters. Continue reading...

• The FDA approved seven new drugs in August 2026 across various medical fields. • These approvals cover treatments for sleep disorders, Alzheimer's disease diagnostics, oncology, rare diseases, autoimmune conditions, and hematology. • Pharmaceutical companies can use these approvals to determine new strategies for market entry, exclusivity timelines, and filing processes.

• NanoViricides announced on September 8, 2026, that it has registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo. • The company reports that NV-387 previously performed better than the drug Remdesivir in a lethal animal model of a viral disease. • This trial addresses a critical gap in healthcare because there is currently no approved vaccine or treatment for the specific strain of ebolavirus causing the expanding outbreak.

• NanoViricides announced on September 8, 2026, that it registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo Ebola virus. • The trial is listed in the Pan African Clinical Trials Database to address the expanding Ebola outbreak in the Democratic Republic of Congo. • This development provides a potential oral treatment option for patients in a region currently facing the largest Ebola outbreak on record.

• The FDA approved Rasonque, a new pancreatic cancer drug developed by Revolution Medicines. • Patients seeking the treatment have found that insurance coverage can take several weeks to catch up with the official approval. • This delay prevents eligible patients from accessing a breakthrough medication during a critical window of their illness.

Victorian One Nation leader tells media he has used methamphetamine, speed and marijuana Victorian One Nation leader, Warren Pickering, has admitted he “made mistakes” in his 20s, including using ecstasy, methamphetamines and marijuana, losing his license multiple times for drink driving and hurting people he loved.But he has denied claims by his ex-partner, published by The Australian, that he smoked ice in front of children and said he was considering legal action against the publication at a press conference on Tuesday. Guardian Australia and the ABC were barred from attending the press conference. Continue reading...

Sarah Khalifa, 39, charged with forming organised criminal gang to manufacture and traffick drugsAn Egyptian court sentenced a well-known television presenter and 11 others to death for manufacturing and trafficking narcotics in a sprawling drug case, official media reported on Saturday.The presenter, Sarah Khalifa, 39, is best known for her programme Mission Impossible, which dealt with issues concerning security and crime. Continue reading...

Healthy middle-aged people deemed to be at higher risk of developing condition among those eligible to participatePeople without memory loss will be offered an experimental Alzheimer’s drug that could stop the development of the condition before dementia symptoms emerge.Healthy middle-aged people deemed to have a higher risk of developing the condition will be eligible to participate in the trial, which is being run by an NHS trust as part of an international clinical trial aiming to prevent dementia. Continue reading...

• Donald Trump has introduced new deals regarding drug pricing as part of his health policy updates. • The latest health reports also cover research on the effects of cannabis edibles on driving and the use of Paxlovid for long Covid. • These developments affect healthcare costs for patients and provide new clinical data for those managing chronic post-viral symptoms.

• Researchers conducted a retrospective review of all novel FDA drug approvals from 2016 through 2024 to analyze the evidence used for authorization. • The study used FDA public records and the ClinicalTrials.gov database to track the number of completed trials and their funding sources. • The findings show that novel drug approvals in the US have been supported by a decreasing number of studies since 2016.

• The Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the new use of the drug avacopan after concluding that pivotal trial data is no longer reliable. • One pivotal clinical study underpinning the drug's license authorization was found to have compromised integrity and reliability. • Patients and providers lose access to a treatment that showed real-world efficacy but can no longer be supported by regulatory benefit-risk standards.

• New migraine prevention guidelines were released on Monday to help physicians navigate treatment options and secure insurance prior authorizations. • The updated framework emphasizes the integration of the newest prevention medications currently available on the market. • These changes matter because a "wealth of new treatment" has emerged, requiring updated clinical standards to ensure patients access modern therapies.

Follow the day’s news liveGet our breaking news email, free app or daily news podcastAustralia will step up its support to fight trans-national drug trafficking flowing through the Pacific, with a $600m package.Anthony Albanese announced the new investment at the Pacific Islands Forum in Palau, which aims to stop the contraband arriving in Australia.This is crucial, and the detail in any reform will determine its success – as will be the overall strength of the proposed Digital Duty of Care reforms that are needed in their own right. It is too easy for Big Tech to design schemes that appear as structural reform but actually suit them just fine. Continue reading...

• A retrospective review of FDA novel drug approvals from 2016 through 2024 reveals a trend of approvals being supported by a decreasing number of completed clinical studies. • Researchers analyzed FDA public records and the ClinicalTrials.gov database to evaluate trial counts, funding sources, and the timing of public result reporting. • The findings highlight a concerning shift toward relying on fewer studies and an increase in industry-funded research to secure drug authorizations.

• A new study reveals that nearly 70% of new drugs approved by the FDA between 2016 and 2024 were granted approval based on a single clinical trial. • Researchers analyzed FDA records and the ClinicalTrials.gov database to track the number of supporting studies, funding sources, and the speed of public result releases. • This shift is attributed to a rise in oncology and rare-disease treatments, evolving trial norms, and disruptions caused by the COVID-19 pandemic.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 31, 2026, that it is preparing for clinical trials of its broad-spectrum drug candidate, NV-387. • The drug utilizes host-mimetic nanomedicine technology designed to treat measles, a disease currently seeing a rise in cases both within the USA and globally. • This development is significant as it aims to provide a revolutionary antiviral treatment that viruses cannot easily escape, addressing a critical gap in measles management.

• The White House is finalizing drug pricing agreements with pharmaceutical companies Bayer, Takeda, and CSL Behring. • These deals are part of a broader initiative by the U.S. government to secure more affordable medication costs through direct negotiations with drugmakers. • The news coincides with the approval of a new cancer therapy, highlighting a period of significant regulatory and financial shifts in the pharma industry.